Vanda Pharmaceuticals Inc. (VNDA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Fanapt | - | 23,545 | - | - |
| Hetlioz | - | 20,872 | - | - |
| Ponvory | - | 5,624 | - | - |
| Total revenues | 52,590 | 50,041 | 47,651 | 50,474 |
| Selling, general and administrative | 64,616 | 50,084 | 37,573 | 39,474 |
| Research and development | 21,990 | 35,712 | 16,776 | 16,661 |
| Cost of goods sold excluding amortization | 2,736 | 3,521 | 2,551 | 2,733 |
| Intangible asset amortization | 1,751 | 1,752 | 1,751 | 1,752 |
| Total operating expenses | 91,093 | 91,069 | 58,651 | 60,620 |
| Loss from operations | -38,503 | -41,028 | -11,000 | -10,146 |
| Other income, net | 3,616 | 3,660 | 4,756 | 4,630 |
| Loss before income taxes | -34,887 | -37,368 | -6,244 | -5,516 |
| Benefit for income taxes | -7,680 | -7,874 | -920 | -998 |
| Net loss | -27,207 | -29,494 | -5,324 | -4,518 |
| Basic (in dollars per share) | -0.46 | -0.5 | -0.09 | -0.08 |
| Basic (in shares) | 58,993,990 | 58,527,775 | 58,261,961 | 58,220,838 |
| Diluted (in dollars per share) | -0.46 | -0.5 | -0.09 | -0.08 |
| Diluted (in shares) | 58,993,990 | 58,527,775 | 58,261,961 | 58,220,838 |